Navigation Links
Combination in Medical News

BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.

NEW YORK, July 31 /PRNewswire-FirstCall/ -- BBV Vietnam S.E.A. Acquisition Corp. (OTC Bulletin Board: BBVUF, BBVVF and BBVWF) (the "Company") announced today that it has signed a non-binding letter of intent with Migami, Inc. to enter into a business combination. Pursuant to the pr...

Drug-Device Combination Market Worth US$18.54 Billion by 2014

WILMINGTON, Delaware, July 28 /PRNewswire/ -- According to a new market research report, 'Drug-Device Combination Market (2009 - 2014)', published by MarketsandMarkets ( http://www.marketsandmarkets.com ), the total drug-device combination market is expected to be worth US$18.54 billion by 201...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

WAYNE, N.J. and EMERYVILLE, Calif., July 22 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met...

96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy

BRIDGEWATER, N.J., July 20 /PRNewswire/ -- Ninety-six week pooled results from two Phase 3 studies (DUET-1 and DUET-2) showed that significantly more treatment-experienced HIV-1-infected adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resi...

Particle Sciences Further Expands Combination Product Development Capabilities

BETHLEHEM, Pa., June 16 /PRNewswire/ -- Particle Sciences Inc., a leading service provider for the development of thermoplastic based Combination Products (drug-eluting devices), has further expanded their development and pilot production capabilities with the addition of a Leistritz ZSE-18mm twin...

QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy

VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Ams...

Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets

Post-hoc analysis of two large clinical trials showed combination therapy helped more patients reach combined targets for HDL, triglycerides and LDL than the pre-determined therapy alone NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Abbott's (NYSE: ABT ) TRILIPIX (R) (fenofibric acid) delay...

QLT announces positive results from the evaluation of Visudyne(R) combination therapy

VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) today announced positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular ...

2-drug combination appears safe and active in metastatic kidney cancer

ORLANDO (May 31, 2009)Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell c...

New treatment combination proves safe for head and neck cancer patients

PITTSBURGH, May 30 Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, Universi...

Study shows drug combination improves outcome for advanced non-small cell lung cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the ...

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institu...

Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP ) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets...

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer

ORLANDO, Fla., May 18 /PRNewswire-USNewswire/ -- Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinica...

HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc.

Business combination should enable HealthWarehouse.com to accelerate expansion of industry-leading $3.50 prescription drug program CINCINNATI, May 15 /PRNewswire-FirstCall/ -- HealthWarehouse.com, Inc., a privately held Delaware corporation, and Clacendix, Inc. (OTC Bulletin Board: IONN.OB) a...

Triple drug combination is promising option to treat metastatic HER2+ breast cancer

ORLANDO Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Ma...

Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions

Longitudinal Data Trends Suggest These Agents Will Face Greater Use of Step Therapy Restrictions and Less Access on Tier 2 on Commercial Health Plans, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary NASHVILLE, Tenn. and GLEN ROCK, N.J., April 28 /PRNewswire/ --...

Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer

Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and hea...

Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells

DENVER - A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report. With further testing of these drugs that are from classes of pharmaceuticals already used in patients, the Mayo research may lead to new...

Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting

NATIONAL HARBOR, Md, April 2 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM ) will present an expert panel of physicians in skin tightening and resurfacing today from 6:00 pm to 8:00 pm at the 29th Annual Meeting of American Society for Lasers in Medicine & Surgery (ASLMS). The ...

3-drug chemotherapy combination increases organ preservation in patients with larynx cancer

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized co...

Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes

TORONTO, March 23 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI , TSX:TTH) announced today that the first patient has been dosed in a clinical study of gastrin analogue TT-223 in combination with a proprietary Lilly GLP-1 analogue, in patients...

Mechanism of Alzheimer's suggests combination therapy needed

Researchers at the University of Illinois at Chicago College of Medicine have discovered a mode of action for mysterious but diagnostic protein snarls found in the brains of Alzheimer's patients that suggests a one-two punch of therapy may be needed to combat the neurodegenerative disease. Alzh...

Drug combination may be effective against deadly melanoma, pilot study shows

DURHAM, N.C. By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy, according to early results of a clinical study conducted by researchers in the Duke Comprehensive Cancer Center. "In this pilot study, ...

PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy

BRIDGEWATER, N.J., Feb. 11 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., today announced the availability of a lower-dose (75 mg) formulation of PREZISTA (darunavir) for pediatric patients with HIV. The announcement follows the FDA approval of PREZISTA,...

Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer

Data Presented at the Society of Gynecologic Oncologists' 40th Annual Meeting on Women's Cancer Proves Superiority of HE4, CA125 and ROMA(TM) Over Existing Tools MALVERN, Pa., Feb. 11 /PRNewswire/ -- New data presented on Saturday during the plenary session at the Society of Gynecologic Oncol...

If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory...

InterMune Reports Results from Triple Combination Study of ITMN-191

- Q12h and Q8h Regimens Deliver Robust Antiviral Effects and Strong Safety Profile - - Phase2b Study Anticipated to Begin in Q2 2009 - - Conference call today at 8:30 a.m. EST - BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today reported to...

Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne

Epiduo(TM) Gel Combines Retinoid and Benzoyl Peroxide in a Single Product; Performs Better than Either Component Alone FORT WORTH, Texas, Jan. 6 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the availability of Epiduo(TM) (adapalene and benzoyl peroxide) Gel 0.1% / 2.5%, the fir...

Holiday Treats and Decorations Can Be a Deadly Combination for Pets

How to Avoid a Trip to the Animal ER this Holiday Season Kansas City, Kan., December 18, 2008 - The veterinary specialists at Veterinary Specialty and Emergency Center of Kansas City (VSEC) wish to warn pet owners of the potential hazards that commonly take place duri...

QLT announces interim results of radical study evaluating Visudyne combination therapy

Mean visual acuity letter scores increased similarly in all treatment groups VANCOUVER, Dec. 16 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) today announced six-month results from an interim analysis for the Phase II RADICAL study (Reduced Fluence Visudyne Anti-...

(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management

ABBOTT PARK, Ill., Dec. 15 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with...

Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management

ABBOTT PARK, Ill., Dec. 15 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with...

Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C

First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need KENILWORTH, N.J., Dec. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and...

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment. Interim results of an ongoing clinical trial evaluati...

European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1

CORK, Ireland, November 27 /PRNewswire/ -- The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA(R) (darunavir) with low-dose ritonavir as part of combination therapy in treatment-naive adults (those who have ...

Best Practice Database Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development

CHAPEL HILL, N.C., Nov. 13 /PRNewswire/ -- Bio-Pharma executives are increasingly finding value in the research products and services offered by Best Practices, LLC and in particular in use of the on-demand benchmark repository known as the Best Practice Database. ( http://www.BestPracticeDat...

Novel 4-drug combination proves safe for lung cancer treatment

CHICAGO - The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderso...

New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development

CHAPEL HILL, N.C., Nov. 4 /PRNewswire/ -- As biopharmaceutical companies focus on line extensions and new product development opportunities, fixed-dose combination (FDC) products have become an increasingly important segment of the market. In an effort to better understand the development stra...

Particle Sciences Develops Zero-Order-Release Combination Device Technology

BETHLEHEM, Pa., Aug. 26 /PRNewswire/ -- Particle Sciences Inc. today announced the development of their "Microreservoir" technology enabling the manufacture of drug-eluting polymer medical devices that release drugs at constant rates over 30 days or more. This technology has already been used ...
Other Tags
(Date:7/29/2014)... bacteria and algae, propel themselves using whip-like appendages ... a millimetre long, function like tiny oars, helping ... cilia are found on the surfaces of many ... liquids over the cell. , Flagella and ... expel pathogens from our airways, they establish the ...
(Date:7/28/2014)... by the University of Arizona has sequenced the complete ... enhance scientists, and agriculturalists, understanding of the growing patterns ... of new rice varieties that are better able to ... hunger challenges. , The paper, "The genome sequence of ... independent domestication," was published online in Nature Genetics ...
(Date:7/28/2014)... A study of juvenile rat brain cells suggests that ... the connections between brain cells are temporary. , The ... PLOS ONE , was conducted by biologists at ... Medical College in New York in response to concerns, ... decade, that exposing children to general anesthetics may increase ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
(Date:7/30/2014)... Pain Free Living web: Superior ... pain relief and improved performance. This new magnetic sports ... a silicone core that is sheathed in nylon soaked ... embedded with scalar energy and Schumann frequency thus making ... has 12 years experience developing magnetic bracelets. We developed ...
(Date:7/30/2014)... Nuanced Media, a specialist in web design ... the Medical Web Design Trends of 2014. The web ... multiple agencies and the medical web design industry throughout the ... the industry grows. Therefore it is important for existing practices ... enjoy most. New trends are defined by advances in the ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
(Date:7/29/2014)... 29, 2014 1Heart Caregiver Services’ ... with focus on Brain Fitness Education brings great ... Brain Fitness Program Director Tee Barr delivered an ... Care unit and the Assisted Living section of ... Enrichment Director Christy Rozsa and Aegis Life Neighborhood ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4
Other Contents